NCT05685173RecruitingPhase 1
A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Aug 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- First submitted
- 28 Apr 2023
- Start date
- 5 Aug 2026
- Lead sponsor
- Regeneron Pharmaceuticals Inc.
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT05685173
- EU CT number
- 2022-502137-26-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 42
- 7 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Hospital Universitario 12 de Octubre Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| Hopital Saint Louis Coordinator of this site? Confirm its status | Paris | France | Recruiting |
| Centre Hospitalier Universitaire de Bordeaux Coordinator of this site? Confirm its status | Pessac | France | Recruiting |
| Institut Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Recruiting |
| Academisch Medisch Centrum Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
| Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.